Ruboxistaurin
| File:Ruboxistaurin.png | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C28H28N4O3 |
| Molar mass | 468.546 g/mol g·mol−1 |
Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic peripheral retinopathy. It is currently being investigated by Eli Lilly and Company.
On February, 2006, Lilly submitted a New Drug Application for ruboxistaurin, and on August 18, 2006, Lilly received an "approvable" letter from the United States Food and Drug Administration for ruboxistaurin,[1] with a request for an additional clinical trial, which would take 5 years to complete.[2]
Mechanism of action
Ruboxistaurin is an inhibitor of PKC-beta.[3]
References
- ^ "Drugs.com, Eli Lilly and Company Announces Approvable Letter Issued by FDA for Arxxant". Retrieved 2008-02-15.
- ^ "Drugs.com, Lilly Announces FDA Requirement of Additional Clinical Trial Before Ruboxistaurin Could Be Approved for Treatment of Diabetic Retinopathy". Retrieved 2008-02-15.
- ^ Clarke M, Dodson PM (2007). "PKC inhibition and diabetic microvascular complications". Best Pract Res Clin Endocrinol Metab. 21 (4): 573–86. doi:10.1016/j.beem.2007.09.007. PMID 18054736.
{{cite journal}}: Unknown parameter|month=ignored (help)
External links
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |